MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has announced that John Johnston, a Non-Executive Director, exercised options for 3,000 shares of common stock and subsequently sold them at prices ranging from $3.800 to $3.870 per share. This transaction, completed under a prearranged trading plan, represents a minor change in Johnston’s holdings, now owning 120,583 shares and retaining options and restricted stock units. MaxCyte continues to position itself as a leader in cell-engineering platform technologies, aiming to transform human health through its ExPERT™ platform.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
